Skip to main content
Erschienen in: Diabetologia 9/2013

01.09.2013 | Article

Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy

verfasst von: S. Wheeler, K. Moore, C. W. Forsberg, K. Riley, J. S. Floyd, N. L. Smith, E. J. Boyko

Erschienen in: Diabetologia | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypotheses

Despite oral hypoglycaemic medications being the most commonly used pharmacological treatments for type 2 diabetes, research is limited on their comparative safety, particularly their effects on overall mortality. We compared mortality risk with monotherapy initiation of four oral hypoglycaemic medications in a nationwide cohort of US veterans with type 2 diabetes.

Methods

We identified new users of oral hypoglycaemic medication monotherapy between 2004 and 2009 who received care for at least 1 year from the Veterans Health Administration. Patients were followed until initial monotherapy discontinuation, addition of another diabetes pharmacotherapy, death or end of follow-up. Mortality HRs were estimated using Cox regression adjusted for potential confounding factors.

Results

Among new users of metformin, sulfonylureas and rosiglitazone (185,360 men, 7,812 women), 4,256 (2.2%) died during follow-up. Average duration of medication use ranged from 1.4 to 1.7 years. Significantly higher mortality risk was seen for glibenclamide (known as glyburide in the USA and Canada) (HR 1.38, 95% CI 1.27, 1.50) or glipizide (HR 1.55, 95% CI 1.43, 1.67) compared with metformin monotherapy, and for glipizide compared with rosiglitazone (HR 1.27, 95% CI 1.01, 1.59) or glibenclamide monotherapy (HR 1.12, 95% CI 1.02, 1.23). A significant sex–rosiglitazone interaction was seen (p = 0.034) compared with metformin monotherapy, with women having a higher HR (HR 4.36, 95% CI 1.34, 14.20) than men (HR 1.19, 95% CI 0.95, 1.49).

Conclusions/interpretations

Significantly higher mortality was associated with glibenclamide, glipizide and rosiglitazone use compared with metformin, and with glipizide use compared with rosiglitazone or glibenclamide. The potential for residual confounding by indication should be considered in interpreting these results.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P (2012) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 156:218–231PubMedCrossRef Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P (2012) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 156:218–231PubMedCrossRef
3.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
4.
Zurück zum Zitat Chien HH, Chang CT, Chu NF et al (2007) Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc 70:473–480PubMedCrossRef Chien HH, Chang CT, Chu NF et al (2007) Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc 70:473–480PubMedCrossRef
5.
Zurück zum Zitat DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541–549PubMedCrossRef DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541–549PubMedCrossRef
6.
Zurück zum Zitat Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS (2003) Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 88:3598–3604PubMedCrossRef Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS (2003) Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 88:3598–3604PubMedCrossRef
7.
Zurück zum Zitat Goldstein BJ, Pans M, Rubin CJ (2003) Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 25:890–903PubMedCrossRef Goldstein BJ, Pans M, Rubin CJ (2003) Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 25:890–903PubMedCrossRef
8.
Zurück zum Zitat Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef
9.
Zurück zum Zitat Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(Suppl):789–830PubMed Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(Suppl):789–830PubMed
10.
Zurück zum Zitat Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRef Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRef
11.
Zurück zum Zitat Kaul S, Diamond GA (2011) Is there clear and convincing evidence of cardiovascular risk with rosiglitazone? Clin Pharmacol Ther 89:773–776PubMedCrossRef Kaul S, Diamond GA (2011) Is there clear and convincing evidence of cardiovascular risk with rosiglitazone? Clin Pharmacol Ther 89:773–776PubMedCrossRef
12.
Zurück zum Zitat Winterstein AG (2011) Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Ther 89:776–778PubMedCrossRef Winterstein AG (2011) Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Ther 89:776–778PubMedCrossRef
13.
Zurück zum Zitat Loke YK, Kwok CS, Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342:d1309PubMedCrossRef Loke YK, Kwok CS, Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342:d1309PubMedCrossRef
14.
Zurück zum Zitat Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201PubMedCrossRef Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201PubMedCrossRef
15.
Zurück zum Zitat Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195PubMedCrossRef Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195PubMedCrossRef
16.
Zurück zum Zitat Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S (2010) Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 19:335–342PubMed Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S (2010) Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 19:335–342PubMed
17.
Zurück zum Zitat Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345–2351PubMedCrossRef Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345–2351PubMedCrossRef
18.
Zurück zum Zitat Evans JM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936PubMedCrossRef Evans JM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936PubMedCrossRef
19.
Zurück zum Zitat Gulliford M, Latinovic R (2004) Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239–245PubMedCrossRef Gulliford M, Latinovic R (2004) Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239–245PubMedCrossRef
20.
Zurück zum Zitat Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248PubMedCrossRef Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248PubMedCrossRef
21.
Zurück zum Zitat Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908PubMedCrossRef Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908PubMedCrossRef
22.
Zurück zum Zitat Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA (2006) Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174:169–174PubMedCrossRef Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA (2006) Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174:169–174PubMedCrossRef
23.
Zurück zum Zitat Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920PubMedCrossRef Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920PubMedCrossRef
25.
Zurück zum Zitat Cowper DC, Kubal JD, Maynard C, Hynes DM (2002) A primer and comparative review of major US mortality databases. Ann Epidemiol 12:462–468PubMedCrossRef Cowper DC, Kubal JD, Maynard C, Hynes DM (2002) A primer and comparative review of major US mortality databases. Ann Epidemiol 12:462–468PubMedCrossRef
27.
Zurück zum Zitat Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389–394PubMedCrossRef Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389–394PubMedCrossRef
28.
Zurück zum Zitat Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus, a cohort study. Ann Intern Med 157:601–610PubMedCrossRef Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus, a cohort study. Ann Intern Med 157:601–610PubMedCrossRef
29.
Zurück zum Zitat Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731PubMedCrossRef Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731PubMedCrossRef
30.
Zurück zum Zitat Kahler KH, Rajan M, Rhoads GG et al (2007) Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 30:1689–1693PubMedCrossRef Kahler KH, Rajan M, Rhoads GG et al (2007) Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 30:1689–1693PubMedCrossRef
31.
Zurück zum Zitat Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135PubMedCrossRef Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135PubMedCrossRef
32.
Zurück zum Zitat Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418PubMedCrossRef Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418PubMedCrossRef
33.
Zurück zum Zitat Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942PubMedCrossRef Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942PubMedCrossRef
34.
Zurück zum Zitat Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2643PubMedCrossRef Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2643PubMedCrossRef
35.
Zurück zum Zitat Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304PubMedCrossRef Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304PubMedCrossRef
36.
Zurück zum Zitat Stevens RJ, Ali R, Bankhead CR et al (2012) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:2593–2603PubMedCrossRef Stevens RJ, Ali R, Bankhead CR et al (2012) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:2593–2603PubMedCrossRef
37.
Zurück zum Zitat Walker AM (1996) Confounding by indication. Epidemiology 7:335–336PubMed Walker AM (1996) Confounding by indication. Epidemiology 7:335–336PubMed
39.
Zurück zum Zitat Shah BR, Laupacis A, Hux JE, Austin PC (2005) Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58:550–559PubMedCrossRef Shah BR, Laupacis A, Hux JE, Austin PC (2005) Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58:550–559PubMedCrossRef
40.
Zurück zum Zitat Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59:437–447PubMedCrossRef Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59:437–447PubMedCrossRef
41.
42.
Zurück zum Zitat Psaty BM, Weiss NS, Furberg CD et al (1999) Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786–790PubMedCrossRef Psaty BM, Weiss NS, Furberg CD et al (1999) Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786–790PubMedCrossRef
Metadaten
Titel
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy
verfasst von
S. Wheeler
K. Moore
C. W. Forsberg
K. Riley
J. S. Floyd
N. L. Smith
E. J. Boyko
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 9/2013
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2958-1

Weitere Artikel der Ausgabe 9/2013

Diabetologia 9/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.